Tag Archives: vitamin B3

Marmite can fight superbugs

You either love it or you hate it, according to the slogan.

And if you are a Marmite fan, the good news is that one of its main ingredients may fight superbugs.

A study found that at very high doses, vitamin B3, also known as niacin, drastically increases the body’s ability to fight the MRSA bacterium, which can cause life-threatening infections if it enters the bloodstream via wounds.

US researchers believe the ingredient – which is also found in beer, bread and other foods containing yeast – could be used to develop new drugs.

Researchers carried out a number of experiments on both rats and human blood, the results of which were published in the Journal of Clinical Investigation.

Overall they found that high doses of vitamin B3 increased the number of neutrophils, a type of white blood cell that kills bacteria.

Adrian Gombart, of Oregon State University, said: ‘This is potentially very significant, although we still need to do human studies. It’s a way to tap into the power of the innate immune system and stimulate it to provide a more powerful and natural response.’

Marmite

Marmite

But the scientists urged caution, as the research used extremely high doses of the vitamin – far more than is in Marmite or vitamin supplements.


Co-author Dr George Liu, also from Oregon State University, said: ‘This vitamin is surprisingly effective in fighting off and protecting against one of today’s most concerning public health threats.’

Dr Gombart stressed that so far there was no evidence to suggest normal diets or conventional-strength B3 supplements could help prevent or treat bacterial infections.

Ten years ago he discovered a human genetic mutation that makes people more vulnerable to bacterial infections.

Further work showed that niacin has the ability to “turn on” anti-microbial genes that help the immune system fight off bacteria.

Vitamin B3 fights MRSA

Vitamin B3 could be the new weapon in the fight against superbugs such as MRSA, researchers have suggested.

US experts found B3, also known as nicotinamide, boosts the ability of immune cells to kill Staphylococcus bacteria.

B3 increases the numbers and efficacy of neutrophils, white blood cells that can kill and eat harmful bugs.

The study, in the Journal of Clinical Investigation, could lead to a “major change in treatment”, a UK expert said.

B3 was tested on Staphylococcal infections, such as the potentially fatal MRSA (Methicillin-resistant Staphylococcus aureus).

Such infections are found in hospitals and nursing homes, but are also on the rise in prisons, the military and among athletes.

The scientists used extremely high doses of B3 – far higher than that obtained from dietary sources – in their tests, carried out both on animals and on human blood.

And the researchers say there is as yet no evidence that dietary B3 or supplements could prevent or treat bacterial infections.

MRSA

MRSA

The researchers say B3 appears to be able to “turn on” certain antimicrobial genes, boosting the immune cells’ killing power.

Prof Adrian Gombart, of Oregon State University’s Linus Pauling Institute, who worked on the research, said: “This is potentially very significant, although we still need to do human studies.

“Antibiotics are wonder drugs, but they face increasing problems with resistance by various types of bacteria, especially Staphylococcus aureus.


“This could give us a new way to treat Staph infections that can be deadly, and might be used in combination with current antibiotics.

“It’s a way to tap into the power of the innate immune system and stimulate it to provide a more powerful and natural immune response.”

Prof Mark Enright, of the University of Bath, said: “Neutrophils are really the front line against infections in the blood and the use of nicotinamide seems safe at this dose to use in patients as it is already licensed for use.

“This could cause a major change in treatment for infections alongside conventional antibiotics to help bolster patients immune system.

“I would like to see in patient clinical trials but cannot see why this couldn’t be used straight away in infected patients.”